siRNA Targeting ECE-1 Partially Reverses Pulmonary Arterial Hypertensionassociated Damage in a Monocrotaline Model
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
AIMS: The aim of this study was to develop a possible treatment for pulmonary arterial hypertension.
BACKGROUND: Pulmonary arterial hypertension (PAH) is a rare disease characterised by a pulmonary arterial pressure greater than 20 mmHg. One of the factors that contribute to PAH is an increase in the production of endothelin-1, a polypeptide that increases vascular resistance in the pulmonary arteries, leading to increased pulmonary arterial pressure and right ventricular hypertrophy.
OBJECTIVE: The objective of this study was to design, synthesize, and evaluate two siRNAs directed against endothelin-1 in a rat model of PAH induced with monocrotaline.
METHODS: Wistar rats were administered monocrotaline (60 mg/kg) to induce a PAH model. Following two weeks of PAH evolution, the siRNAs were administered, and after two weeks, right ventricular hypertrophy was evaluated using the RV/LV+S ratio, blood pressure, weight, and relative expression of ECE-1 (Endothelin-converting enzyme-1) mRNA (messenger RNA) by RT-PCR (real-time PCR).
RESULTS: The monocrotaline group showed an increase in the hypertrophy index and in ECE-1 mRNA, as well as a significant decrease in weight compared to the control group, while in the monocrotaline + siRNA group, a significant decrease was observed in the relative expression of ECE-1 mRNA, as well as in right ventricular hypertrophy.
CONCLUSIONS: Based on the above information, we conclude that the administration of siRNAs directed to ECE-1 decreases the damage associated with PAH.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Current molecular pharmacology - (2024) vom: 08. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Blancas-Napoles, Citlali Margarita [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Endothelin-1 |
|---|
| Anmerkungen: |
Date Revised 11.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.2174/0118761429283384240226074921 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369551737 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369551737 | ||
| 003 | DE-627 | ||
| 005 | 20240311233154.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240311s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/0118761429283384240226074921 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1323.xml |
| 035 | |a (DE-627)NLM369551737 | ||
| 035 | |a (NLM)38465437 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Blancas-Napoles, Citlali Margarita |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a siRNA Targeting ECE-1 Partially Reverses Pulmonary Arterial Hypertensionassociated Damage in a Monocrotaline Model |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 11.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a AIMS: The aim of this study was to develop a possible treatment for pulmonary arterial hypertension | ||
| 520 | |a BACKGROUND: Pulmonary arterial hypertension (PAH) is a rare disease characterised by a pulmonary arterial pressure greater than 20 mmHg. One of the factors that contribute to PAH is an increase in the production of endothelin-1, a polypeptide that increases vascular resistance in the pulmonary arteries, leading to increased pulmonary arterial pressure and right ventricular hypertrophy | ||
| 520 | |a OBJECTIVE: The objective of this study was to design, synthesize, and evaluate two siRNAs directed against endothelin-1 in a rat model of PAH induced with monocrotaline | ||
| 520 | |a METHODS: Wistar rats were administered monocrotaline (60 mg/kg) to induce a PAH model. Following two weeks of PAH evolution, the siRNAs were administered, and after two weeks, right ventricular hypertrophy was evaluated using the RV/LV+S ratio, blood pressure, weight, and relative expression of ECE-1 (Endothelin-converting enzyme-1) mRNA (messenger RNA) by RT-PCR (real-time PCR) | ||
| 520 | |a RESULTS: The monocrotaline group showed an increase in the hypertrophy index and in ECE-1 mRNA, as well as a significant decrease in weight compared to the control group, while in the monocrotaline + siRNA group, a significant decrease was observed in the relative expression of ECE-1 mRNA, as well as in right ventricular hypertrophy | ||
| 520 | |a CONCLUSIONS: Based on the above information, we conclude that the administration of siRNAs directed to ECE-1 decreases the damage associated with PAH | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Endothelin-1 | |
| 650 | 4 | |a Endothelin-1 converting enzyme | |
| 650 | 4 | |a Endothelin-1. | |
| 650 | 4 | |a Monocrotaline | |
| 650 | 4 | |a Pulmonary arterial hypertension | |
| 650 | 4 | |a Small interfering RNA | |
| 700 | 1 | |a Cabrera-Becerra, Sandra Edith |e verfasserin |4 aut | |
| 700 | 1 | |a Sierra-Sánchez, Vivany Maydel |e verfasserin |4 aut | |
| 700 | 1 | |a Ocampo-Ortega, Sergio Adrian |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia-Rubio, Vanessa Giselle |e verfasserin |4 aut | |
| 700 | 1 | |a Romero-Nava, Rodrigo |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Fengyang |e verfasserin |4 aut | |
| 700 | 1 | |a Hong, Enrique |e verfasserin |4 aut | |
| 700 | 1 | |a Aguilera-Méndez, Asdrúbal |e verfasserin |4 aut | |
| 700 | 1 | |a Villafaña, Santiago |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current molecular pharmacology |d 2008 |g (2024) vom: 08. März |w (DE-627)NLM185149499 |x 1874-4702 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:08 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/0118761429283384240226074921 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 08 |c 03 | ||